News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Why FDA Delay on Brodalumab is Actually Great News For Valeant (VRX)



11/30/2016 6:29:21 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
As if all the scandals, management fiascos, and ultra bearish calls even after the stock collapsed an astonishing 93% from its 2015 highs weren’t enough, Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) was dealt another blow to the gut on November 8th when the Food and Drug Administration announced that it was delaying its decision on potential blockbuster psoriasis drug brodalumab by three months.

At first glance by any cursory logic, an FDA delay is a bad thing, especially considering that the efficacy of brodalumab over current Johnson & Johnson (NYSE:JNJ) blockbuster Stelara is obvious and understood, even by the FDA panel that reviewed the drug back in July. However, as counterintuitive as it may sound, the delay may actually be a great sign for embattled Valeant, drowning in debt and in desperate need of a blockbuster shot in the arm.

Read at News Release


comments powered by Disqus
   
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES